Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$30.27 - $43.79 $4,056 - $5,867
134 Added 26.27%
644 $20.8 Million
Q4 2023

Mar 01, 2024

BUY
$31.31 - $44.19 $15,968 - $22,536
510 New
510 $21.5 Million

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Creekmur Asset Management LLC Portfolio

Follow Creekmur Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Creekmur Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Creekmur Asset Management LLC with notifications on news.